《NDA 小组的科学意见: 3'-唾液乳糖的安全》

  • 来源专题:食物与营养
  • 编译者: xinning
  • 发布时间:2015-07-28
  • Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on 2'-O-fucosyllactose as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 29 July 1997 concerning the scientific aspects and the presentation of information necessary to support applications for the placing on the market of novel foods and novel food ingredients (NFIs) and the preparation of initial assessment reports under Regulation (EC) No 258/97. The assessment is based on the data supplied in the original application, the initial assessment by the competent authority of Ireland, the concerns and objections of the other Member States and the responses of the applicant.……

相关报告
  • 《NDA 小组的科学意见:乳糖-N-新四糖的安全性》

    • 来源专题:食物与营养
    • 编译者:xinning
    • 发布时间:2015-07-28
    • Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on lacto-N-neotetraose as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 29 July 1997 concerning the scientific aspects and the presentation of information necessary to support applications for the placing on the market of novel foods and novel food ingredients (NFIs) and the preparation of initial assessment reports under Regulation (EC) No 258/97. The assessment is based on the data supplied in the original application, the initial assessment by the competent authority of Ireland, the concerns and objections of the other Member States and the responses of the applicant. Lacto-N-neotetraose (LNnT) is a synthetic tetrasaccharide consisting of d-galactose, N-acetyl-d-glucosamine, d-galactose and d-glucose, which is produced by using d-lactose as a starting raw material.
  • 《对NDA组合的科学意见: 乳酸克鲁维酵母的β 半乳糖苷酶以及肠胃不适的减轻》

    • 来源专题:食物与营养
    • 编译者:xinning
    • 发布时间:2015-07-28
    • Following an application from Cross Vetpharm Group UK Ltd, submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to β-galactosidase from Kluyveromyces lactis in Colief® and a reduction of gastrointestinal discomfort. The scope of the application was proposed to fall under a health claim referring to children’s development and health. The food that is the subject of the health claim is ‘Colief®/lactase enzyme produced by controlled fermentation of Kluyveromyces lactis’. Ingested lactose is hydrolysed by lactase, an enzyme of the microvillus membrane of the enterocytes, into its components, glucose and galactose. The exogenous enzymes which are used to hydrolyse lactose are microbial β-galactosidases. The β-galactosidase which is the subject of the health claim is derived from the yeast Kluyveromyces lactis. The Panel considers that the food, β-galactosidase from Kluyveromyces lactis in Colief®, which is the subject of the health claim, is sufficiently characterised in relation to the claimed effect.……